Company intelligence / Profile preview
Selexel
not specified, Franceselexel.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Selexel is a French biotechnology company developing therapeutic solutions in oncology using innovative RNA interference technologies. Its lead programs are in preclinical development and focus on neoplasms, with one program targeting the androgen receptor pathway for castration-resistant prostate cancer. No clinical results have been reported as of May 2025.
- Therapeutic areas
- Oncology
- Modalities
- Small interfering RNASmall molecule
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Selexel.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Selexel.